ABL1 and acute lymphoblastic leukemia: Inhibition of the constitutively activated PI3K/AKT/mTOR signaling pathway with a triple combination of small molecule inhibitors targeting mTOR, BCR-ABL and CK2 resulted in a highly significant and potent inhibition of cellular growth of SupB15 B-ALL cells (Fig. 6).